drugset / Trial / NCT02954263

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

NCT02954263 ↗

Phase 1 Completed 40 enrolled Theravance Biopharma
RandomizedParallel-groupDouble-blindBasic science

Summary

Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects

Timeline

Start
2016-11
Primary completion
2017-02
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TD-1439 Unknown — —

Indications

No indication recorded.